Granuloblastosis

Granuloblastosis is a rare and severe form of chronic myeloid leukemia (CML), characterized by the accumulation of immature granulocyte precursors in the bone marrow. It is a late-stage disease, typically occurring after the chronic phase of CML has been treated with tyrosine kinase inhibitors (TKIs) such as imatinib. The disease is marked by the presence of granulocyte precursors in the bone marrow, which can lead to anemia, thrombocytopenia, and neutropenia. Granuloblastosis is associated with a poor prognosis, with a median overall survival of around 12 months. Treatment options are limited and often ineffective, with most patients eventually succumbing to the disease. The exact cause of granuloblastosis is not fully understood, but it is believed to be related to the development of resistance to TKIs and the accumulation of genetic mutations in the bone marrow. Research is ongoing to develop new treatment strategies for granuloblastosis and improve patient outcomes.